











"Infectious diseases physicians are alarmed by the prospect that effective antibiotics may not be available to treat seriously ill patients in the near future. There simply aren't enough new drugs in the pharmaceutical pipeline to keep pace with drug resistant bacterial infections, so-called 'superbugs."

Plasma – An Overview Plasma is the regarded as the fourth state of matter which is similar to the gaseous state but with certain degrees of ionisation and a higher energy content. Produced on laboratory scale by flowing gas through an electric field which drives the ionization, excitation and dissociation of gaseous molecules. This produces high densities of reactive oxygen and

This produces high densities of reactive oxygen and nitrogen species (RONS), charged particles (ions and electrons), radiation (from UV to IR), and electromagnetic fields.

Non-Thermal Plasma

- Thermal plasmas have for many years been used in sterilization of medical equipment, packaging, implants
- Advantages include rapid bactericidal activity and access to narrow/confined recesses
- Recently atmospheric pressure, low temperature ('non-thermal' or 'cold') plasmas have been developed
- Typically less than 40°C at point of application
- Capable of delivering unique reactive dry chemistry at ambient temperatures to delicate surfaces – potentially viable tissues
- This has given rise to the emerging field of 'Plasma Medicine'



Overview: Why APNTP?

- Provides highly reactive environment at ambient temperature and pressure.
- Tunability of plasma chemistry which makes it possible to optimise for different applications
- Low capital and operational cost.
- Personnel and environment friendly.
 Utilisation of virtually non-toxic gases (He, Ar, O₂, N₂)
 Absence of harmful residues.
- Multiple conformations (power input, electrode configurations, plasma geometry)



<section-header>

















































Hosted by Prof. Jean-Yves Maillard, Cardiff University A Webber Training Teleclass www.webbertraining.com





SS30-D2 Mucoid PA strain

4 6

é











Combined effect of Alginate and eDNA on log ₁₀ reduction of P. aeruginosa viabili				
Exposure	log ₁₀ Reduction in PA01 Viability			
(minutes)	0mcg/ml	0 mcg/ml	5 mcg/ml DNA	50 mcg/ml
` ´	DNA & 0%	DNA & 0.5	& 0.5 %	DNA & 0.5 %
	Alginate	% Alginate	Alginate	Alginate
0.25	0.29±0.09	0.08±0.06	0.07±0.08	0.03±0.03
0.5	0.42±0.02	0.15±0.08	0.09±0.07	0.05±0.05
1	0.85±0.1	0.73 ±0.7	0.67±0.17	0.48±0.06
2	1.49±0.1	0.8±0.17	0.74±0.09	0.60±0.12





Summary

- Rapid bactericidal effect, more than one target, more than reactive one species involved
- >4 log reduction in 48 hr P. aeruginosa biofilm in 4 minutes
- Biphasic biofilm kill curve may indicate a 'shielding effect' from surface layers of biofilm or;
- Sequestering of active species by cellular component of sacrificial outer layer of biofilm
- Plasma interaction with liquid has implications for planktonic kill rate

 rate of propagation of reactive species
- Multiple cellular targets (interactions with lipid membrane, protein, DNA)
- Effect of biofilm subpopulations (persisters) must be considered in chronic or longterm infections
- Biofilm components are critical mediators of bacterial biofilm tolerance to non-thermal plasma treatments

Future Directions (QUB Plasma Medicine Group)

- Invest Northern Ireland funded Proof of Concept Grant
- Development of a portable system based on the device described for hospital control of biofilms, planktonic bacteria and viral pathogens
- Ward Testing infection control (2014)
- Safety and Biocompatibility testing
- Phase I safety trials
- Trials in animals (and eventually patients) topical wounds







